YUE DA INTL (00629.HK): Appoints Dr. Wang Li as Independent Non-Executive Director and Remuneration Committee Chairman; Re-Compliant with Listing Rules
NewTimeSpace News: On 14 August 2026, Yue Da International Holdings Limited (stock code: 00629.HK) announced that Dr. Wang Li has been appointed as an independent non-executive director, chairman of the remuneration committee, and a member of the audit committee and the nomination committee of the Company, with effect from 14 August 2026.
The Company previously disclosed in its announcements dated 15 May 2026 and 15 June 2026 that it failed to comply with Rules 3.10(1), 3.10A, 3.21, 3.25, 3.27A and 13.92(2) of the Listing Rules due to an insufficient number and ratio of independent non-executive directors and non-compliant compositions of the audit committee, remuneration committee and nomination committee. According to the announcement, following the appointment of Dr. Wang, together with the earlier appointment of Ms. Deng Luna as an independent non-executive director and chairman of the audit committee on 15 June 2026, the Company has fully re-complied with the requirements of the above Listing Rules provisions.
Dr. Wang, aged 69, holds a bachelor's degree in pharmacy from Sichuan Medical College and a doctoral degree in pharmacy from Hokuriku University, and was a visiting scholar at the School of Medicine of Nagoya University. With more than 40 years of research experience in pharmacology and toxicology, she previously served as professor and doctoral supervisor at West China Hospital of Sichuan University, and currently serves as chief scientist of Chengdu Huaxi Haigi Pharmaceutical Technology Co., Ltd. / the National Chengdu Preclinical Safety Evaluation Center for New Drugs, as well as chief scientist of Chengdu Haifeng Biotechnology Co., Ltd. Dr. Wang has received a second-class National Science and Technology Progress Award and a first-class award of the Ministry of Education for scientific and technological progress, was named a national model of March 8 Red Banner Pacesetters in 2017, and was elected one of Sichuan's top ten annual figures in science and technology innovation in 2023.
The Company has entered into an appointment letter with Dr. Wang for a term of three years from 14 August 2026, which will be automatically renewed unless otherwise agreed in writing or terminated in accordance with its terms. Dr. Wang will hold office until the Company's first annual general meeting following her appointment, at which she is required to offer herself for re-election, and thereafter will retire by rotation and be eligible for re-election at annual general meetings in accordance with the bye-laws. She is entitled to an annual director's fee of RMB 100,000. Dr. Wang has confirmed her independence with reference to the factors set out in Rules 3.13(1) to (8) of the Listing Rules, and that she has no financial or other interests in, or connections with, the Group's business or any core connected person of the Company.
